

Prolidase-dependent regulation of collagen biosynthesis

A. Surazynski · W. Milyk · J. Palka ·
J. M. Phang

Received: 25 November 2007 / Accepted: 7 February 2008 / Published online: 5 March 2008
© Springer-Verlag 2008

Abstract Prolidase [EC.3.4.13.9] is a cytosolic imidodipeptidase, which specifically splits imidodipeptides with C-terminal proline or hydroxyproline. The enzyme plays an important role in the recycling of proline from imidodipeptides (mostly derived from degradation products of collagen) for resynthesis of collagen and other proline-containing proteins. The enzyme activity is up-regulated by β_1 -integrin receptor stimulation. The increase in the enzyme activity is due to its phosphorylation on serine/threonine residues. Collagen is not only structural component of extracellular matrix. It has been recognized as a ligand for integrin receptors, which play an important role in signaling that regulate ion transport, lipid metabolism, kinase activation and gene expression. Therefore, changes in the quantity, structure and distribution of collagens in tissues may affect cell signaling, metabolism and function. Several line of evidence suggests that prolidase activity may be a step-limiting factor in the regulation of collagen biosynthesis. It has been shown in different physiologic and pathologic conditions. It is of great importance during wound healing, inflammation, aging, tissue fibrosis and possibly skeletal abnormalities seen in Osteogenesis Imperfecta. The mechanism of prolidase-dependent regulation of collagen biosynthesis was found at both transcriptional and post-transcriptional levels. In this study,

we provide evidence for prolidase-dependent transcriptional regulation of collagen biosynthesis. The mechanism was found at the level of NF- κ B, known inhibitor of type I collagen gene expression. Modulation of integrin-dependent signaling by stimulatory (i.e. thrombin) or inhibitory (i.e. echistatin) β_1 -integrin ligands or by nitric oxide donors (i.e. DETA/NO) affect prolidase at post-transcriptional level. All those factors may represent novel approach to pharmacotherapy of connective tissue disorders.

Keywords Prolidase · Collagen metabolism · β_1 -integrin signaling

Introduction

Prolidase (E.C.3.4.13.9) is a cytosolic exopeptidase widely distributed in man and animals (Myara et al. 1984). The enzyme cleaves imidodi- and imidotriptides with C-terminal proline or hydroxyproline (Mock et al. 1990). The reaction catalyzed by prolidase is presented on Fig. 1. The best substrate for the prolidase and simultaneously the most abundant imidodipeptide is glycyl-proline (Mock et al. 1990). The imidodipeptides come from intracellular degradation of procollagen (intracellular form of collagen), collagen (extracellular form of collagen), degradation of other proline-containing proteins (sources representing very small percentage of imidodipeptides) and dietary proteins (Adibi and Mercer 1973; Jackson et al. 1975). Intestinal hydrolases do not recognize the inherent tertiary amide bonds (Myara et al. 1984), therefore, termination of ingested protein degradation take place intracellularly. It seems that prolidase activity (despite the collagen gene expression) may be a step-limiting factor in regulation of collagen biosynthesis. Cytosolic location of the

A. Surazynski · W. Milyk · J. Palka (✉)
Department of Medicinal Chemistry,
Medical University of Białystok, ul. Kilińskiego 1,
15-089 Białystok, Poland
e-mail: pal@amb.edu.pl

J. M. Phang
Laboratory of Comparative Carcinogenesis,
Center for Cancer Research,
National Cancer Institute at Frederick, Frederick, MD, USA

is linked through its tertiary nitrogen to the carbonyl of N-terminal amino acid residue (Mock et al. 1990).

Only the *trans* isomer of X-Pro dipeptides where X is any amino acid is cleaved by the enzyme (King et al. 1986; Lin and Brandts 1979). In respect to proline in X-Pro dipeptide, the L-configuration is essential (Sjostrom et al. 1973). Replacement of proline by hydroxyproline or sarcosine results in 50-fold loss in hydrolytic efficiency, whereas replacement of proline with thiazolidinecarboxylic acid leads to a substrate that is about three times more efficiently hydrolyzed than glycyl-proline (Hui and Lajtha 1978; Sjostrom et al. 1973).

Kinetic study of these substrates led to the conclusion that a functional group with a pK_a value of 6.6 is essential to the hydrolytic mechanism. The authors proposed that the group is water molecule rendered acidic by coordination to the metalloenzyme complex. The water molecule is displaced from the active site metal ion by the substrate, forming enzyme–substrate complex (Mock et al. 1990). A model for the enzyme–substrate complex has been proposed in which the active site Mn^{+2} cation is simultaneously ligated to the prolyl carboxyl group and the amido oxygen of the preceding residue of the *trans* X-Pro dipeptides (King et al. 1989). The scheme of the hypothetical complex is presented in Fig. 3. The highest susceptibility to the action of prolidase evoke alanyl-proline, glycyl-proline, valyl-proline and several fold lower than other imidodipeptides (Mock et al. 1990).

Recent data show that prolidase may also inactivate organophosphorous compounds (acetylcholinesterase-inhibiting drugs) suggesting that prolidase evokes broader

substrate specificity than that was initially thought (Wang et al. 2006).

Prolidase deficiency

Prolidase deficiency is rare autosomal recessive disorder characterized by massive imidodipeptiduria, skin lesions, recurrent infections, mental retardation and elevated proline-containing dipeptides in plasma (Freij et al. 1984; Goodman et al. 1968; Isemura et al. 1979; Pierard et al. 1984; Powell and Maniscalco 1976; Scriver 1964; Umemura 1978). The incidence of the disease is 1–2 cases per million births (Lemieux et al. 1984; Naughten et al. 1984; Lupi et al. 2006b). The estimate of disease prevalence will of course be low if symptomatic cases are not diagnosed as prolidase deficiency. On the other hand, some prolidase deficiency cases do not develop disease manifestations. Perhaps every person with prolidase deficiency will show symptoms if lifespan is sufficiently long but at present there is no explanation for the variation. The most characteristic symptoms of prolidase deficiency are connected to the metabolic changes in the connective tissue. All symptomatic cases had skin lesions as diffuse telangiectasia, purpuric rash, crusting erythematous dermatitis or progressive ulcerative dermatitis, particularly on the lower legs (Phang and Scriver 1989).

Mutations in prolidase gene are the molecular basis for prolidase deficiency. It has been found in several mutated alleles of prolidase gene. The mutations are present in exons 8, 10, 11, 12, 14 and 15, as well as in introns 4, 6, 7, 11 (Endo and Matsuda 1991; Ledoux et al. 1991; Lupi et al. 2006b). The products of mutated alleles are not able to form active (dimeric) enzyme (Tanoue et al. 1991) or undergo rapid degradation (Ledoux et al. 1996).

Role of prolidase in metabolism of collagen and other proline-containing proteins

The substrates (imidodipeptides) for prolidase come from intracellular degradation of procollagen, collagen and other proline or hydroxyproline-containing peptides, including dietary proteins. Prolidase catalyzes the final step of their degradation into free amino acids in the cytoplasm (Fig. 4). It seems that primary biological function of the enzyme in mammals involves the metabolism of collagen degradation products and the recycling of proline from X-Pro dipeptides for collagen resynthesis (Jackson et al. 1975; Yaron and Naider 1993). Therefore, in prolidase deficiency the connective tissue is affected, particularly its main component collagen. One of the clinical symptoms of the disease is skin lesion. The pathogenetic mechanism leading to the




Fig. 3 Hypothetical model of prolidase–substrate (alanylproline) interaction (according to King et al. 1989). N nitrogen, O oxygen, L regions of prolidase binding manganese




Fig. 4 Extracellular and intracellular sources of imidodipeptides (IDP), representing substrate for fibroblast's prolidase and its role in reutilization of proline for procollagen synthesis. *IDP* imidodipeptides, *CDP* collagen degradation products, *HYP* hydroxyproline, *Pro* proline, *X* any amino acid

skin changes is poorly understood. It is suggested that the pathomechanism of the disease is due to microangiopathy. Probably disturbances of collagen synthesis and degradation are an underlying process in which imidodipeptides (mainly glycyl-proline) may play an important role. It has been found that imidodipeptides stimulated intracellular collagen degradation. In fibroblast cultures from prolidase deficient patients, an increase in rapidly degraded collagen and decrease in proline pool has been found in comparison to control cells (Chamson et al. 1989). Collagen which accounts for about one-third of total body proteins represent polypeptide containing the highest amount of imino-bonds compared to all known proteins. In $\alpha 1$ subunit (1464 amino acids) of type I procollagen, proline is coupled to glycine 119 times and in $\alpha 2$ subunit (1366 amino acids) 106 times. In fully hydroxylated collagen, proline may occur either as hydroxylated amino acid in doublet of glycyl-hydroxyproline (gly-hyp) and unhydroxylated amino acid, glycyl-proline (Gly-pro). In $\alpha 1$ or $\alpha 2$ subunit of matured, hydroxylated collagen, Gly-pro may occur at least 25 times (Jackson et al. 1975). Therefore, degradation of collagen produces large quantities of Gly-pro, the substrate for prolidase.

Collagen is essential for the maintenance of connective tissue. The interaction between cells and ECM proteins, mediated by the integrin family of cell surface receptors can regulate cellular gene expression, differentiation, growth and other functions (Akiyama et al. 1990; Bissel 1981; Carey 1991; Donjacour and Cunha 1991). The functional link between collagen and prolidase activity was found in cultured human skin fibroblast treated with anti-inflammatory drugs (Miltyk et al. 1996), pyrroline 5-carboxylate (Miltyk and Palka 2000), during experimental aging of the cells (Palka et al. 1996), experimental inflammation in chondrocytes (Karna et al. 2006), cell surface integrin receptor ligation (Palka and Phang 1997), Osteogenesis Imperfecta (Galicka et al. 2001) and several

malignant diseases (Karna et al. 2000, 2002; Cechowska et al. 2006).

Collagen is not the only protein in which proline is coupled to glycine. Similar sequence has been found in heavy chains of immunoglobulins and C_{1q} (Reid and Porter 1976). Since prolidase deficiency is accompanied by immunodeficiency (Phang and Scriver 1989) it cannot be excluded that the phenomenon is a result of disturbances in biosynthesis of immunoglobulin and C_{1q} . In view of the collagen-like amino acid sequence in both substances, it seems that there may be an immunologic deficit related to the prolidase deficiency.

In most cases of prolidase deficiency, mental retardation accompanies the disease (Phang and Scriver 1989). It may result from decrease in proline concentration in central nervous system. It has been found that proline play an important role in modulation of glutamatergic neurons (Freneau et al. 1992). It is possible that modulation of prolidase activity may serve as a regulator of proline concentration in central nervous system. Not only brain prolidase may evoke such function. Prolidase of erythrocytes may cleave the dipeptides that penetrate the erythrocyte membrane and produce amino acids. Because the erythrocytes cannot utilize amino acids, it was suggested that the principal role of the amino acid transport system present in this cells is to efflux the amino acids from the hydrolysis of absorbed peptides (King and Kuchel 1984). In view of the facts, prolidase deficiency may be responsible for the decrease in proline pool in central nervous system and disturb the function of glutamatergic neurons.

Although the role of prolidase in pathobiochemistry of the disorders is not well understood, it seems that prolidase-dependent regulation of transcription factors activity may be an underlying mechanism. Recently, we have shown that overexpression of prolidase resulted in increased nuclear hypoxia inducible factor (HIF-1 α) level and elevated expression of HIF-1 α dependent gene products, vascular endothelial growth factor (VEGF) and glucose transporter-1 (Glut-1). The activation of HIF-1-dependent transcription was shown by prolidase-dependent activation of hypoxia response element (HRE)-luciferase expression. We used an oxygen-dependent degradation domain (ODD)-luciferase reporter construct as a surrogate for HIF-1 α as an in situ prolyl-hydroxylase assay. Since this reporter is degraded by VHL-dependent mechanisms, the increased levels of luciferase observed with prolidase expression reflected the decreased HIF-1 α prolyl hydroxylase activity. Additionally, the differential expression of prolidase in two breast cancer cell lines showed prolidase-dependent differences in HIF-1 α levels. These findings show that metabolism of imidodipeptides by prolidase plays a previously unrecognized role in angiogenic signaling (Surazynski et al. 2007).

Since prolidase serves a unique function in all cell types, therefore the mechanism(s) and factor(s) involved in prolidase activity regulation are of special interest.

Prolidase-dependent regulation of collagen biosynthesis

Collagen is known as a ligand for $\alpha 2\beta 1$ integrin. Previously, it has been shown that $\beta 1$ -integrin receptor is involved in signaling that regulates collagen biosynthesis (Ivaska et al. 1999) and prolidase activity (Palka and Phang 1997). Stimulated $\beta 1$ -integrin receptor induces autophosphorylation of non-receptor focal adhesion kinase pp125FAK (FAK), which is then capable of interaction with adaptor proteins, such as Grb2, through Src or SHc proteins. This interaction allows to activate further cascade of signaling pathway through Sos, Ras and Raf proteins and subsequently two mitogen activated protein (MAP) kinases ERK1 and ERK2 (Juliano and Haskill 1993; Seger and Krebs 1995). The result of this phenomenon is induction of transcription factors that stimulate expression of genes for many proteins involved in the regulation of cell growth, differentiation and metabolism (Labat-Robert and Robert 2000). The evidence for the coordinate regulation of prolidase activity and collagen biosynthesis by $\beta 1$ -integrin signaling comes from the study on the effect of echistatin (disintegrin) and thrombin (integrin activator) in human dermal fibroblasts. Echistatin was found to inhibit collagen biosynthesis and prolidase activity and expression, as well as FAK, Sos and MAPK expression, while thrombin in every case evoked an opposite effect (Surazynski et al. 2005a). Similarly, coordinate regulation of prolidase activity and collagen biosynthesis was found at the level of signaling by insulin-like growth factor (IGF-I), the most potent stimulator of collagen biosynthesis (Miltyk et al. 1998).

Studies on inhibition of prolidase activity by nickel chloride in CHO cells that are auxotrophic for proline, but contain prolidase showed that prolidase in these cells is important limiting factor for collagen production (Miltyk et al. 2005). The same correlation was found in case of stimulation of prolidase by nitric oxide (NO) donors. As shown in time course experiment, NO stimulate both prolidase activity and collagen biosynthesis in fibroblasts (Fig. 5). The mechanism for the stimulatory effect of NO on prolidase activity was found at the level of post-translational modification of prolidase. Increase in the enzyme activity was due to increase in the enzyme phosphorylation on serine/threonine residue (Surazynski et al. 2005b).

Several data suggested that prolidase-dependent regulation of collagen biosynthesis may take place at the transcriptional level. We provided evidence that transfection of colorectal cancer cells with prolidase vector




Fig. 5 Prolidase activity (a) and collagen biosynthesis (b) measured in NIH 3T3—fibroblast that had been treated with nitric oxide (NO) donor—DETA/NO at 250 μ M for 24 and 48 h. Prolidase activity was measured according to the method of Myara et al. (1982) and collagen biosynthesis by the method of Peterkofsky et al. (1982)

drastically inhibited NF- κ B expression (Fig. 6). The transcription factor is well-recognized inhibitor of expression of $\alpha 1$ and $\alpha 2$ subunits of type I collagen (Kouba et al. 1999; Rippe et al. 1999; Miltyk et al. 2007). Another evidence for the role of prolidase in regulation of NF- κ B expression provides experiment showing that inhibition of prolidase




Fig. 6 Prolidase activity (a) and NF- κ B expression (b) in cells with a gain-of-function experimental model by transfecting RKO cells with a prolidase cDNA expression plasmid and obtained stable transfectants. Prolidase activity was measured according to the method of Myara et al. (1982) and NF- κ B expression by Western immunoblot

activity by Cbz-pro contributed to up-regulation of NF- κ B expression in fibroblasts (Fig. 7).

Although the mechanism of this phenomenon is not known, it seems that products of prolidase activity, proline or hydroxyproline may modulate processing of NF- κ B in a similar way as it was described with respect to HIF-1 α (Surazynski et al. 2007). The activation of NF- κ B requires degradation of the cytoplasmic I κ B α by the ubiquitin–proteasome pathway. Increase in prolidase activity that result in increase in free proline or hydroxyproline may contribute to inhibition of degradation of I κ B α and subsequently inhibition of NF- κ B activity and translocation to the nucleus. However, the hypothesis requires to be proved. Whatever is the mechanism of the observed phenomena the data suggest that prolidase-dependent regulation of collagen biosynthesis may take place at both transcriptional and post-transcriptional levels.

Conclusions and perspectives

Although prolidase was found to play important role in the metabolism of various tissues most intriguing questions still remain unanswered: What factors are involved in prolidase activity regulation? What mechanisms explain the distant manifestation of the prolidase deficiency? What

is the role of imidodipeptides in the metabolism of various tissues? What is the role of prolidase in pathology, including cancer?

Much of the work has to be done before the role of prolidase in metabolism of various tissues will be understood and before an effective treatment of prolidase deficiency will be developed.

References

- Adibi SA, Mercer DW (1973) Protein digestion in human intestine as reflected in luminal, mucosal and plasma amino acid concentration after meals. *J Clin Invest* 52:1586–1591
- Akiyama SK, Nagata K, Yamada K (1990) Cell surface receptors for extracellular matrix components. *Biochim Biophys Acta* 1031:91–110
- Ball SP, Tongue N, Gibaud A, Lependu J, Mollicone R, Gerard R, Oriol R (1991) The human chromosome 19 linkage group FUT1(H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9. *Ann Hum Genet* 55:225–233
- Barua PK, Neiders ME, Topolnycky A, Zambon JJ, Birkedal-Hansen H (1989) Purification of an 80,000-M, glycylprolyl peptidase from *Bacteroides gingivalis*. *Infect Immun* 57:2522–2528
- Bissel M (1981) How does extracellular matrix direct gene expression? *J Theor Biol* 99:31–68
- Boright AP, Scriver CR, Lancaster GA, Choy F (1989) Prolidase deficiency: biochemical classification of alleles. *Am J Hum Genet* 44:731–740
- Carey DJ (1991) Control of growth and differentiation of vascular cells by extracellular matrix. *Ann Rev Physiol* 53:161–177
- Cechowska-Pasko M, Palka JA, Wojtukiewicz MZ (2006) Enhanced prolidase activity and decreased collagen content in breast cancer tissue. *Int J Exp Path* 87:289–296
- Chamson A, Voigtlander V, Myara I, Frey J (1989) Collagen biosynthetic anomalies in prolidase deficiency: effect of glycyl-L-proline on the degradation of newly synthesized collagen. *Clin Physiol Biochem* 7(3–4):128–136
- Donjacour AA, Cunha GR (1991) Stromal regulation of epithelial function. *Cancer Treat Res* 53:335–364
- Endo F, Hata A, Indo Y, Motohara K, Matsuda I (1987a) Immunochemical analyses of prolidase deficiency and molecular cloning of a cDNA for prolidase of human liver. *J Inherit Metab Dis* 10:305–307
- Endo F, Motohara K, Indo Y, Matsuda I (1987b) Immunochemical studies of human prolidase with monoclonal antibodies: absence of the subunit of prolidase in a patient with prolidase deficiency. *Pediatr Res* 22:627–633
- Endo F, Tanoue A, Ogata T, Motohara K, Matsuda I (1988) Immunoaffinity purification of human prolidase. *Clin Chim Acta* 176:143–150
- Endo F, Tanoue A, Nakai H, Hata A, Indo Y, Titani K, Matsuda I (1989) Primary structure and gene localization of human prolidase. *J Biol Chem* 264:4476–4481
- Endo F, Matsuda I (1991) Molecular basis of prolidase (Peptidase D) deficiency. *Mol Biol Med* 8:117–127
- Freij BJ, Levy HL, Dudin GL, Mutasim D, Deeb M, Der Kaloustian VA (1984) Clinical and biochemical characteristics of prolidase deficiency in siblings. *Am J Med Genet* 19:561–566
- Freneau RT, Caron MG, Blakely RD (1992) Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain. *Neuron* 8:915–926
- Galicka A, Wolczynski S, Anchim T, Surazynski A, Lesniewicz R, Palka J (2001) Defects of type I procollagen metabolism




Fig. 7 Prolidase activity (a), collagen biosynthesis (b) and NF- κ B expression (c) measured in fibroblast treated with different concentration of Cbz-Pro (prolidase inhibitor) for 24 h. The same methodology for the assays as in legend to Fig. 6 was employed

- correlated with decrease of prolydase activity in a case of lethal osteogenesis imperfecta. *Eur J Biochem* 268:2172–2178
- Ghosh M, Grunden AM, Dunn DM, Weiss R, Adams WW (1998) Characterization of native and recombinants forms of an unusual cobalt-dependent proline dipeptidase (Prolidase) from the hyperthermophilic archaeon *Pyrococcus furiosus*. *J Bacteriology* 180:4781–4789
- Goodman SI, Solomons CC, Muschenheim F, Macintyre CA, Miles B, O'Brien D (1968) A syndrome resembling lathyrism associated with iminodipeptiduria. *Am J Med* 45:152–159
- Hui KS, Lajtha A (1978) Peptidase activity in brain: comparison with other organs. *J Neurochem* 30:321–328
- Isemura M, Hanyu T, Gejyo F, Nakazawa R, Igarashi R, Matsuo S, Ikeda K, Sato Y (1979) Prolidase deficiency with imidodipeptiduria. A familial case with and without clinical symptoms. *Clin Chim Acta* 93:401–409
- Ivaska J, Reunanen H, Westermarck J, Koivisto L, Kahari VM, Heino J (1999) Integrin $\alpha 2 \beta 1$ mediates isoform-specific activation of p38 and up-regulation of collagen gene transcription by a mechanism involving the $\alpha 2$ cytoplasmic tail. *J Cell Biol* 147:401–416
- Jackson SH, Dennis AN, Greenberg M (1975) Imino-peptiduria. A genetic defect in recycling collagen: a method for determining prolidase in red blood cells. *Can Med Assoc J* 113:759–763
- Juliano RL, Haskill S (1993) Signal transduction from the extracellular matrix. *J Cell Biol* 120:577–585
- Karna E, Surazynski A, Palka J (2000) Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. *Int J Exp Pathol* 81:341–347
- Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P, Palka J (2002) Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. *Int J Exp Pathol* 83:239–245
- Karna E, Mityk W, Palka J, Jarzabek K, Wolczynski S (2006) Hyaluronic acid counteracts interleukin-1-induced inhibition of collagen biosynthesis in cultured human chondrocytes. *Pharmacol Res* 54:275–281
- King GF, Kuchel PW (1984) A proton NMR study of imidodipeptide transport and hydrolysis in the human erythrocyte. *Biochem J* 220:553–560
- King GF, Middlehurst CR, Kichel PW (1986) Direct NMR evidence that prolidase is specific for the trans isomer of imidodipeptide substrate. *Biochemistry* 25:1054–1059
- King GF, Crossley MJ, Kuchel PW (1989) Inhibition and active-site modelling of prolidase. *Eur J Biochem* 180:377–384
- Kouba DJ, Chung KY, Nishiyama T, Vindevoghel L, Kon A, Klement JF, Uitto J, Mauviel A (1999) Nuclear factor-kappa B mediates TNF-alpha inhibitory effect on alpha 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. *J Immunol* 162:4226–4234
- Labat-Robert J, Robert L (2000) Interaction between cells and extracellular matrix: signaling by integrins and the elastin-laminin receptor. *Prog Mol Subcell Biol* 25:57–70
- Ledoux P, Scriver C, Hechtman P (1991) Molecular heterogeneity and variable clinical expression at the PEPD locus. *Am J Hum Genet* 49:411–415
- Ledoux P, Scriver CR, Hechtman P (1996) Expression and molecular analysis of mutations in deficiency. *Am J Hum Genet* 59:1035–1039
- Lemieux B, Auray-Blais C, Giguere R, Shapcott D (1984) Prolidase deficiency: detection of cases by a newborn urinary screening program. *J Inher Metab Dis* 7:145–148
- Lin LN, Brandts JF (1979) Role of *cis-trans* isomerism of the peptide bond in protease specificity. Kinetic studies on small proline-containing peptides and on polyproline. *Biochemistry* 18:43–47
- Lupi A, Rossi E, Vaghi P, Gallanti A, Cetta G, Forlino A (2005) N-benzoyloxycarbonyl-L-proline: an in vitro and in vivo inhibitor of prolidase. *Biochim Biophys Acta* 1744:157–163
- Lupi A, Della Torre S, Campari E, Tenni R, Cetta G, Rosii A, Forlino A (2006a) Human recombinant prolidase from eucaryotic and procaryotic sources. Expression, purification, characterization and long-term stability studies. *FEBS J* 273:5466–5478
- Lupi A, Rossi E, Campari E, Pecora F, Lund AM, Elcioglu NH, Gultepe M, Di Rocco M, Cetta G, Forlino A (2006b) Molecular characterization of six patients with prolidase deficiency: identification of the first small duplication in the prolidase gene and of a mutation generating symptomatic and asymptomatic outcomes within the same family. *J Med Genet* 43:e58
- Mityk W, Karna E, Palka J (1996) Inhibition of prolidase activity by non-steroid anti-inflammatory drugs in cultured human skin fibroblasts. *Pol J Pharmacol* 48:609–613
- Mityk W, Karna E, Wolczynski S, Palka J (1998) Insulin-like growth factor I-dependent regulation of prolidase activity in cultured human skin fibroblasts. *Mol Cell Biochem* 189:177–183
- Mityk W, Palka J (2000) Potential role of pyrroline 5-carboxylate in regulation of collagen biosynthesis in cultured human skin fibroblasts. *Comp Biochem Physiol A Mol Integr Physiol* 125:265–271
- Mityk W, Surazynski A, Kasprzak KS, Fivash MJ Jr, Buzard GS, Phang JM (2005) Inhibition of prolidase activity by nickel causes decreased growth of proline auxotrophic CHO cells. *J Cell Biochem* 94:1210–1217
- Mityk W, Karna E, Palka JA (2007) Prolidase-independent mechanism of camptothecin-induced inhibition of collagen biosynthesis in cultured human skin fibroblasts. *J Biochem* 141:287–292
- Mock WL, Green PC, Boyer KD (1990) Specificity and pH dependence acylproline cleavage by prolidase. *J Biol Chem* 265:19600–19605
- Mock WL, Green PC (1991) Mechanism and inhibition of prolidase. *J Biol Chem* 265:19606–19610
- Mock WL, Zhuang H (1991) Chemical modification locates guanidinyl and carboxylate groups within the active site of prolidase. *Biochem Biophys Res Commun* 180:401–406
- Myara I, Charpentier C, Lemonnier A (1982) Optimal conditions for prolidase assay by proline colorimetric determination: application to imidodipeptiduria. *Clin Chim Acta* 125:193–205
- Myara I, Charpentier C, Lemonnier A (1984) Minireview: prolidase and prolidase deficiency. *Life Sci* 34:1985–1998
- Naughten ER, Proctor SP, Levy HL, Coulombe JT, Amplola MG (1984) Congenital expression of prolidase defect in prolidase deficiency. *Ped Res* 18:259–264
- Palka JA, Mityk W, Karna E, Wolczyński S (1996) Modulation of prolidase activity during in vitro aging of human skin fibroblasts. The role of extracellular matrix collagen. *Tokai J Exp Clin Med* 21:207–13
- Palka JA, Phang JM (1997) Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptor. *J Cell Biochem* 67:166–175
- Peterkofsky B, Chojkier M, Bateman J (1982) Determination of collagen synthesis in tissue and cell culture system. In: Furthmayr (ed) *Immunocytochemistry of the extracellular matrix*. CRC Press, Boca Raton, pp 19–47
- Phang JM, Scriver CR (1989) In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) *The metabolic basis of inherited disease*. Disorders of proline and hydroxyproline metabolism. McGraw Hill, New York, pp 577–597
- Pierard GE, Cornil F, Lapiere CHM (1984) Pathogenesis of ulcerations in deficiency of prolidase. *Am J Dermatopathol* 6:491–498
- Powell GH, Maniscalco RM (1976) Bound hydroxyproline excretion following gelatin loading in prolidase deficiency. *Metabolism* 25:503–508

- Reid KBM, Porter RR (1976) A collagen-like amino acid sequence in a polypeptide chain of human C1q (a subcomponent of the first component of complement). *Biochem J* 155:19–23
- Richter AM, Lancaster GA, Choy FYM, Hechtman P (1989) Purification and characterization of activate human erythrocyte prolidase. *Biochem Cell Biol* 67:34–39
- Rippe RA, Schrum LW, Stefanovic B, Solís-Herruzo JA, Brenner DA (1999) NF-kappaB inhibits expression of the alpha1(I) collagen gene. *DNA Cell Biol* 18:751–761
- Scriver CR (1964) Glycyl-proline in urine of humans with bone disease. *Can J Physiol Pharmacol* 42:357–364
- Seger R, Krebs EG (1995) The MAPK signaling cascade. *FEBS J* 9:726–735
- Sjostrom H, Noren O, Josefsson L (1973) Purification and specificity of pig intestinal prolidase. *Biochim Biophys Acta* 327:457–470
- Sjostrom H (1974) Enzymatic properties of pig intestinal proline dipeptidase. *Acta Chem Scand B* 28:802–808
- Sjostrom H, Noren O (1991) Structural properties of pig intestinal proline dipeptidase. *Biochim Biophys Acta* 359:177–185
- Surazynski A, Sienkiewicz P, Wolczynski S, Palka J (2005a) Differential effect of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrin-mediated signaling. *Pharmacol Res* 51:217–221
- Surazynski A, Liu Y, Mityk W, Phang JM (2005b) Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. *J Cell Biochem* 96:1086–1094
- Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow K, Liu Y, Phang JM (2008) Extracellular matrix and HIF-1 signaling: the role of prolidase. *Int J of Cancer* (in press)
- Tanoue A, Endo F, Matsuda I (1990) Structural organization of the gene for human prolidase (peptidase D) and demonstration of a partial gene deletion in a patient with prolidase deficiency. *J Biol Chem* 265:11306–11311
- Tanoue A, Endo F, Akaboshi I, Oono T, Arata J, Matsuda I (1991) Molecular defect in siblings with prolidase deficiency and absence or presence of clinical symptoms. *J Clin Invest* 87:1171–1176
- Umehura S (1978) Studies on a patient with iminodipeptiduria. II. Lack of prolidase activity in blood cells. *Physiol Chem Phys* 10:279–285
- Uramatsu M, Liu G, Uramatsu S, Zhang M, Wang W, Nakayama K, Manabe M, Kodama H (2007) Different effects of sulfur amino acids on prolidase and prolinase activity in normal and prolidase-deficient human erythrocytes. *Clin Chim Acta* 375:129–135
- Wang SH, Zhi QW, Sun MJ (2006) Dual activities of human prolidase. *Toxicol In Vitro* 20:71–77
- Yaron A, Naider F (1993) Proline-dependent structural and biological properties of peptides and proteins. *Crit Rev Biochem Mol Biol* 28:31–81